Dapsone‐induced methemoglobinemia
Open Access
- 18 January 2011
- Vol. 117 (15) , 3485-3492
Abstract
BACKGROUND: Dapsone, used for Pneumocystis jiroveci (PCP) prophylaxis, is associated with increased risk of methemoglobinemia. Absence of cytochrome b5 reductase enzyme activity causes congenital methemoglobinemia, but its role in dapsone‐associated methemoglobinemia is unknown. The authors sought to elucidate drug‐related risk factors for dapsone‐associated methemoglobinemia in pediatric oncology patients, including contribution of cytochrome b5 reductase enzyme activity.METHODS: Among 167 pediatric patients treated for hematologic malignancies or aplastic anemia who received dapsone for PCP prophylaxis, demographic and dapsone treatment data were retrospectively collected. Drug‐related risk factors were evaluated by Cox proportional hazards, and in a cross‐sectional subgroup of 40 patients, cytochrome b5 reductase enzyme activity was assessed.RESULTS: Methemoglobinemia (median methemoglobin level = 9.0% [3.5‐22.4]) was documented in 32 (19.8%) patients. There was a 73% risk reduction in methemoglobinemia with dosing ≥20% below the target dose of 2 mg/kg/d (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.09‐0.78; P = .016), whereas methemoglobinemia risk was increased with dosing ≥20% above the target dose (HR, 6.25; 95% CI, 2.45‐15.93; P < .001). Sex, body mass index, and age were not associated with increased risk. Cytochrome b5 reductase enzyme activity did not differ by methemoglobinemia status (median 8.6 IU/g hemoglobin [Hb]; [5.5‐12.1] vs 9.1 IU/g Hb; [6.7‐12.7]). No patient developed PCP on dapsone.CONCLUSIONS: Methemoglobinemia occurred in almost 20% of pediatric oncology patients receiving dapsone for PCP prophylaxis. Higher dapsone dosing is associated with increased risk. A cross‐sectionally acquired cytochrome b5 reductase enzyme activity level was not associated with methemoglobinemia risk. Studies are needed to define biologic correlates of methemoglobinemia and evaluate lower dapsone doses for PCP prophylaxis. Cancer 2011. © 2011 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Severe hemolysis and methemoglobinemia following fava beans ingestion in glucose-6-phosphatase dehydrogenase deficiency—case report and literature reviewEuropean Journal of Pediatrics, 2009
- Dapsone-Induced Methemoglobinemia: Case Report and Literature ReviewAmerican Journal of Therapeutics, 2007
- Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patientsPediatric Blood & Cancer, 2007
- Pneumocystis pneumonia in children receiving chemotherapyPediatric Blood & Cancer, 2007
- Prophylaxis ofPneumocystis cariniipneumonia with atovaquone in children with leukemiaCancer, 2007
- Failure of intravenous pentamidine prophylaxis to prevent pneumocystis pneumonia in a pediatric hematopoietic stem cell transplant (HSCT) patientPediatric Blood & Cancer, 2006
- Dapsone-Induced Methemoglobinemia after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2006
- Dapsone-induced methemoglobinemia in pediatric oncology patients: Case examplesJournal of Pediatric Oncology Nursing, 2001
- ALTERNATIVE DAPSONE DOSAGE REGIMEN FOR PROPHYLAXIS OF PNEUMOCYSTIS CARINII PNEUMONIAThe Pediatric Infectious Disease Journal, 1996
- Studies on dapsone induced haemolytic anaemia.British Journal of Dermatology, 1979